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Introduction: Previous exploratory analysis of epidermal growth
factor receptor (EGFR) mutational status in tumor samples from
randomized clinical studies suggested that patients with activating
mutation of the EGFR had better survival than those harboring
wild-type EGFR.
Methods: We analyzed the EGFR sequence of tumor samples from
advanced stage non-small cell lung cancer patients previously par-
ticipated in treatment clinical trials. Responses to chemotherapy and
survival of EGFR mutation-positive or -negative patients were
compared.
Results: Tumor samples from 122 patients were available for
analysis. EGFR mutation was present in 58 patients (47.5%). In 105
stage IIIB/IV patients, there was a nonstatistically significant trend
toward a higher chemotherapy response rate of patients with mu-
tated EGFR than those with wild-type EGFR (44.6% versus 30.6%,
p  0.162). Female, never-smoking, and adenocarcinoma patients
lived longer than male (p  0.0139), smoking (p  0.0045), or
nonadenocarcinoma (p  0.0151) patients. There was no difference
in the survival of patients with mutated or wild-type EGFR (p 
0.2159). There was no difference in progression-free survival of
first-line chemotherapy between patients with wild-type or mutation
in EGFR (6.6 months versus 6.1 months).
Conclusion: There is a nonstatistically significant trend toward a
higher chemotherapy response rate in patients with mutated EGFR
than those with wild-type EGFR. EGFR gene mutation is not a
predictive biomarker for progression-free and overall survival to
cytotoxic chemotherapy in East Asians with advanced non-small
cell lung cancer.
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The use of epidermal growth factor receptor (EGFR) ty-rosine kinase inhibitors (TKIs) in advanced stage non-
small cell lung cancer (NSCLC) has led to the discovery of a
group of patients harboring activating mutations of EGFR.1,2
The mutational sites clustered between exons 18 and 21, in
the tyrosine kinase-binding domain. Despite the success in
the treatment of some advanced stage chemotherapy-treated
NSCLC patients,3,4 gefitinib failed to improve survival com-
pared with placebo in a large randomized trial.5 Conversely,
erlotinib has demonstrated survival advantage when com-
pared with placebo in patients previously treated with com-
bination chemotherapy.6
Gefitinib or erlotinib when combined with first-line
chemotherapy regimen failed to improve survival compared
with chemotherapy alone in four large randomized stud-
ies.7–10 Patients harboring activating mutation of EGFR may
preferentially benefit from TKIs treatment.11 Retrospective
studies were performed in these studies testing the tumor
samples for EGFR mutation in the archived specimen. The
results of the analysis were surprising in that gefitinib or
erlotinib adding to standard combination chemotherapy failed
to improve survival over standard chemotherapy alone even
in subsets of patients harboring EGFR mutations. However,
in these analyses, the survival of EGFR mutation-positive
patients was significantly longer than those without EGFR
mutations in groups of patients who received chemotherapy
alone without gefitinib or erlotinib.12,13 In the Iressa Pan-Asia
Survival Study (IPASS) comparing gefitinib with paclitaxel
plus carboplatin as the first-line therapy in Asian patients,
patients with activating mutation of EGFR had a statistically
higher response rate (47.3% versus 23.5%) than patients
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without EGFR mutations when they received paclitaxel plus
carboplatin. The progression-free survivals (PFSs) were not
different between patients with and patients without EGFR
mutation in the chemotherapy arm.14 Thus, it is hypothesized
that patients with EGFR mutations seem to respond better to
combination chemotherapy.
To explore whether the different chemotherapy treat-
ment outcomes of advanced stage NSCLC patients with or
without EGFR mutations in previous biomarker analysis12,13
can be applied in East Asian NSCLC patients, in whom the
EGFR mutation rates are highest among the world, we ret-
rospectively collected archived tumor samples from advanced
NSCLC patients previously accrued to clinical trials and
tested the tumor samples for EGFR mutations. The previ-
ously recorded clinical data were retrieved and combined.
Survival times of these patients were updated. PFS, and
overall survival (OS), and responsiveness to chemotherapy
were compared by different clinical predictors and EGFR
mutational status.
PATIENTS AND METHODS
Eligibility Criteria to Select Patients
Advanced stage NSCLC patients accrued to treatment
clinical trials between 1994 and 2005 from two Asian med-
ical centers were identified. Patients were eligible for the
study if they have archived tissue blocks for analysis of tumor
EGFR gene. In addition to the informed consent and approval
by local ethics committees to participate in prior clinical
trials, this retrospective study was further approved by local
ethics committees. Clinical parameters such as gender, smok-
ing status, stage, treatments and response to treatments, and
progression time point were captured by previous data. In-
vestigators’ evaluation of the response was used in this study,
despite independent reviews were used in some of the trials
(and the results were not available to the sites). The World
Health Organization criteria of response were used. In sec-
ond-line treatment studies, recorded response to first-line
chemotherapy in the medical record was used in this study.
Additional data such as survival time updates are retrospec-
tively collected from medical records.
EGFR Gene Analysis
Sequence analysis of exons 18 to 21 of EGFR genes
were described previously.15 In short, DNA was extracted
from paraffin blocks. Fragments of DNA between exons 18
and 21 were amplified by the nested-reverse transcription
polymerase chain reaction. The resulted amplified products
were subjected to DNA sequence analysis by DNA se-
quencer.
Statistics Considerations
PFS time of first-line combination chemotherapy was
defined as the time from first dose of chemotherapy to
documented radiologic progression. OS time was defined as
the time from first dose of chemotherapy to death. Response
rates to chemotherapy or EGFR mutation status in different
groups of patients were compared with 2 test or Fisher’s
exact test. Log-rank test was used to compare PFS and OS in
patients with different clinical-pathologic or molecular pa-
rameters. A significant relationship with survival (p  0.10)
was used as a criterion for including a variable in the
multivariate stepwise modeling procedure. Multivariate anal-
ysis was performed using the Cox proportional hazards model
with a forward selection procedure to create a final model.
The final model was chosen on the basis of those variables for
which p  0.05. SPSS software version 13.0 (SPSS Inc.,
Chicago, IL) was used for all analyses.
RESULTS
Demographics of Patients
One hundred twenty-two patients were selected from
14 clinical trials. The baseline characteristics of all pa-
tients are listed in Table 1. The first-line chemotherapy
regimens used are listed in Table 2. The age and gender
distributions were similar to prior reports of the same
group of patients in clinical trials in East Asia. The
percentages of adenocarcinoma and nonsmokers were
higher compared with other trials because of the referral
characteristics of these two medical centers. Twenty-one
percent of patients had prior surgery and recurred. This
rate is higher than the prior surgery rates of other clinical
trial population because of the selection effect from the
requirement of adequate tumor samples for EGFR gene
analysis. Seventeen locally advanced stage IIIA/IIIB pa-
tients who entered a neoadjuvant chemotherapy trial were
not included in response evaluation and survival analysis.
EGFR Mutation in Tumor Samples
Fifty-eight patients (47.5%) were tested positive for
activating EGFR mutations. The mutation sites of these
patients were exon 19 deletions in 27 patients, L858R
mutation in 21 patients, and other types of EGFR muta-
tions (K708_E709del and T710N, M825R, I744T, E866G,
D855G and L844P, L799R, D761V, and V845M) in 10
patients. The rates of EGFR mutation in each subset of
patients are listed in Table 1. The rates of EGFR mutation
in each chemotherapy regimen are listed in Table 2. The
rates of EGFR mutation are 44.8, 61.1, and 50.0% in
platinum doublets, nonplatinum doublets, and other regi-
mens, respectively. Never smokers and former smokers
had statistically higher EGFR mutation rate than current
smokers. The EGFR mutation rate in 17 patients with
locally advanced stage was low (11.8%).
Response to Chemotherapy
The responses to first-line combination chemotherapy
in stage IIIB/IV patients are listed in Table 3. Forty-four
patients (41.9%, 95% confidence interval 32.5–51.3) re-
sponded to the first-line chemotherapy treatment. None of the
clinical-pathologic factors or EGFR mutation status was able
to predict for response to initial chemotherapy. Female pa-
tients, never or former smokers, and patients with EGFR-
mutated tumors had statistically insignificant higher response
rates.
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Prediction for Progression-Free Survival Time
of First-Line Chemotherapy
The tumor response was evaluated regularly in patients
participated in clinical trials of first-line chemotherapy. PFS
of each subset of patients was shown in Figure 1. Female
patients and patients who responded to the chemotherapy had
statistically better PFS. There was no difference in PFS
between patients with or without EGFR mutations in their





All 105 44 (41.9%)
Gender
Men 61 19 (31.1%)
Women 44 21 (47.7%) 0.105a
Smoking status
Current 29 8 (27.6%)
Former 21 9 (42.9%)
Never 55 23 (41.8%) 0.379b
Histology
Adenocarcinoma 91 35 (38.5%)
Nonadenocarcinoma 14 5 (35.7%) 1.000a
Age (yr)
65 71 26 (36.6%)
65 34 14 (41.2%) 0.673a
EGFR
Mutation 56 25 (44.6%)
Wild-type 49 15 (30.6%) 0.162a
a Fisher’s exact test.
b 2 test.
EGFR, epidermal growth factor receptor.
TABLE 1. Demography and EGFR Mutation Rates in All Patients and Metastatic Patients
Clinical Characteristics
All Metastatic
Wild-Type EGFR (%) Mutated EGFR (%) p Wild-Type EGFR (%) Mutated EGFR (%) p
Total 64 (52.5) 58 (47.5) 49 (46.7) 56 (53.3)
Age (yr)
65 4 (10.0) 36 (90.0) 13 (38.2) 21 (61.8)
65 60 (73.2) 22 (26.8) 0.334a 36 (50.7) 35 (49.3) 0.297a
Gender
Men 44 (58.7) 31 (41.3) 31 (50.8) 30 (49.2)
Women 20 (42.6) 27 (57.4) 0.096a 18 (40.9) 26 (59.1) 0.330a
Smoking status
Current 27 (71.1) 11 (28.9) 18 (62.2) 11 (37.9)
Former 9 (39.1) 14 (60.9) 8 (38.1) 13 (61.9)
Never 28 (45.9) 33 (54.1) 0.017b 23 (41.8) 32 (58.2) 0.142b
Histology
Adenocarcinoma 47 (48.5) 50 (51.5) 42 (46.2) 49 (53.8)
Nonadenocarcinoma 17 (68.0) 8 (32.0) 0.115a 7 (50.0) 7 (50.0) 1.000a
Staging
Locally advanced IIIA/IIIB 15 (88.2) 2 (11.8)
Metastatic IIIB/IV 49 (46.7) 56 (53.3) 0.001a
Prior surgery
Yes 16 (61.5) 10 (38.5) 16 (61.5) 10 (38.5)
None 48 (50.0) 48 (50.0) 0.377a 33 (41.8) 46 (58.2) 0.112a
Gefitinib or erlotinib use
Yes 17 (31.5) 37 (68.5) 17 (31.5) 37 (68.5)
None 47 (69.1) 21 (30.9) 0.000a 32 (62.7) 19 (37.3) 0.002a
a Fisher’s exact test.
b 2 test.
EGFR, epidermal growth factor receptor.




Gemcitabine and cisplatina 70 32 (45.7)
Gemcitabine and epirubicin 11 9
Vinorelbine and cisplatinb 11 5
Docetaxel and cisplatin 9 2
Gemcitabine 7 4
Paclitaxel and gemcitabine 6 2
Pemetrexed and cisplatin 5 4
Paclitaxel and cisplatin 1 0
Docetaxel and gemcitabine 1 0
Docetaxel, vinorelbine, and cisplatin 1 0
a 17 locally advanced.
b Six oral vinorelbine, two combined with cetuximab.
EGFR, epidermal growth factor receptor.
Lin et al. Journal of Thoracic Oncology • Volume 5, Number 9, September 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1426
tumor samples. On multivariate regression analysis, only
female gender was an independent factor predicting for
longer PFS with a hazard ratio of 0.36 (95% confidence
interval 0.26–0.62).
Prediction for Overall Survival
The OS in each subset of patients are shown in Figure 2.
In univariate log-rank test, female gender, never or former
smoking status, and adenocarcinoma histology predicted for
longer OS. These three variables with statistical significance
on univariate analysis were selected for multivariate regres-
sion analysis. Only female gender was an independent factor
predicting for longer OS according to the Cox proportional
hazards model results with a hazard ratio of 0.44 (95%
confidence internal 0.07–0.96). Patients who responded to
first-line chemotherapy had statistically insignificantly better
survival time. There was no difference in OS between pa-
tients with or without EGFR mutations. Patients receiving
gefitinib or erlotinib as salvage second- or third-line treatment
in East Asia may have significant survival advantages.6,16,17
The median survival time for 49 patients in this study who
received EGFR TKIs was 27.1 months, statistically better
than 56 patients who did not had a chance to take gefitinib or
erlotinib (13.8 months).
DISCUSSION
EGFR mutation is a potent predictor for EGFR TKI
but not for cytotoxic chemotherapy. The common clinical
characteristics predictive of tumor response to EGFR
TKI18 were basically reflective of the higher incidence of
EGFR mutations. The presence of EGFR activating muta-
tions defines a specific group of NSCLC patients who have
exceptionally good response to EGFR TKI.19 Our study
has shown that in predominantly nonsmoking East Asian
population, detection of EGFR mutations with conven-
tional DNA sequencing methodology in tumor samples is
not a predictive factor for survival improvement to first-
line chemotherapy if EGFR TKI was not used as a salvage
therapy. Our observation of higher tumor response rate
(44.6% versus 30.6%) in patients with EGFR mutation is
compatible with the IPASS data (47.3% versus 23.2%).
The lack of statistical significance is likely related to the
small sample size. However, mutational status is not pre-
FIGURE 1. Progression-free survival in terms of (A) gender, (B) smoking status, (C) histology, (D) responses to chemotherapy
(CT), (E) receptor tyrosine kinase inhibitors (RTKI), and (F) mutational status of the epidermal growth factor receptor (EGFR).
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dictive of PFS. Limitation on duration of chemotherapy is
the likely explanation. In IPASS, there is also no signifi-
cant difference in PFS to first-line chemotherapy between
EGFR mutation-positive and -negative population.20 The
OS data from IPASS are pending. In our retrospective
study, we found similar OS between the two groups,
because EGFR TKI was not available as a salvage therapy
in the time when these clinical trials were conducted.
Although the OS is not different between patients with
mutated EGFR and those with wild-type EGFR, female gender
is an independent factor prognostic of longer OS. This is in line
with other studies. Prospective studies have consistently found
that the death rate from lung cancer is higher in men than
women, both in the absence and presence of active smoking.21
Median OS of patients with either wild-type or activat-
ing mutation of EGFR in this study are longer than the
expected 8 to 10 months. This observation could be partly
explained by the East Asian ethnicity. The median OS of the
four arms of a large randomized phase III study in Japan was
between 12 and 14 months.22 The median OS of Taiwanese
NSCLC patients enrolled in clinical trials between 1997 and
1999 was 12 months.21 In a comparative study between two
arms of different studies using the same paclitaxel plus
carboplatin regimen, a 3-month difference in median survival
was demonstrated between Japanese patients and Caucasian
patients.23 Subgroup analyses of recent international studies
have confirmed this prior observation that East Asian NSCLC
had an overall better prognosis. The hazard ratio of OS of
East Asian versus Caucasian patients was 0.65 in a random-
ized study comparing gemcitabine plus cisplatin with pem-
etrexed plus cisplatin.24
The long OS of EGFR mutation-negative patients in
this study may be due to small sample size and selection bias
in that most patients in this series are adenocarcinoma and
light or never-smoking patients. Patients with these charac-
ters generally had better prognosis. The direct sequencing
EGFR test used in this study is not sensitive enough to detect
all EGFR mutation samples. Heterogeneity of EGFR muta-
tion in sites of tumor may also resulted in false-negative
detection results.25 False-negative results in this study may
result in mixing of some EGFR mutation-positive patients in
the EGFR mutation-negative patient group and obscure the
difference of OS between the two. The false-negative EGFR
tests may have resulted in a 10 to 20% response rates in
EGFR wild-type patients treated with gefitinib in prior East
Asian studies.11,26–28 Unfortunately at the time of analysis,
FIGURE 2. Overall survival in terms of (A) gender, (B) smoking status, (C) histology, (D) responses to chemotherapy (CT), (E)
receptor tyrosine kinase inhibitors (RTKI), and (F) mutational status of the epidermal growth factor receptor (EGFR).
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we were not able to use more sensitive detection methods
such as that reported recently.29
In conclusion, this study supports the IPASS finding
that EGFR mutation to be associated with a higher tumor
response rate to chemotherapy, but EGFR mutation is
not a predictive biomarker for PFS and OS to cytotoxic
chemotherapy.
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